BNP/CALL/MODERNA/100/0.1/19.12.25 Share Price

DE000PC1G815

Real-time Boerse Frankfurt Warrants 04:20:27 28/06/2024 pm IST
4.38 ^EUR	+0.69%

Current month	-26.89%
1 month	-45.28%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MODERNA, INC.

Latest news about MODERNA, INC.

Carisma Therapeutics Debuts Moderna Collaboration With Solid Tumors Investigative Study; Shares Soar Premarket	02:58pm	MT
US CDC advisers recommend updated COVID vaccines for those six months and older	28/06	RE
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna	28/06	CI
GSK Shares Slump After CDC Narrows Age Recommendation for RSV Shots	27/06	DJ

More news

Quotes 5-day view

Date	Price	Change
28/24/28	4.38	+0.69%
27/24/27	4.35	-2.25%
26/24/26	4.45	-18.94%
25/24/25	5.49	0.00%
24/24/24	5.49	+3.39%

Real-time Boerse Frankfurt Warrants

Last update June 28, 2024 at 04:20 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	MODERNA, INC.
Issuer	BNP Paribas
WKN	PC1G81
ISIN	DE000PC1G815
Date issued	08/12/2023
Strike	100 $
Maturity	19/12/2025 (540 Days)
Parity	10 : 1
Emission price	1.81 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	8.11 €
Lowest since issue	1.79 €
Delta	0.77x
Omega	1.977
Premium	21.36x
Gearing	2.57x
Moneyness	1.212
Difference Strike	-21.18 $
Difference Strike %	-21.18%
Spread	0.01 €
Spread %	0.23%
Theoretical value	4.405
Implied Volatility	61.28 %
Total Loss Probability	50.50 %
Intrinsic value	1.978
Present value	2.427
Break even	147.17 €
Theta	-0.02x
Vega	0.04x
Rho	0.06x

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

More about the company